Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRNS NASDAQ:KYTX NASDAQ:PBYI NASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$1.36-6.8%$1.24$0.64▼$2.92$55.38M-0.71260,508 shs45,471 shsKYTXKyverna Therapeutics$6.63-6.1%$4.49$1.78▼$7.73$305.31M3.72844,444 shs639,978 shsPBYIPuma Biotechnology$5.12-1.7%$4.79$2.32▼$6.07$262.43M1.39502,574 shs428,615 shsRENBLunai Bioworks$1.54+21.7%$2.04$1.13▼$21.00$250.24M0.543.75 million shs880,400 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics-6.85%-5.91%+23.64%+32.68%+14.29%KYTXKyverna Therapeutics-6.09%+20.11%+64.93%+64.52%+47.01%PBYIPuma Biotechnology-1.73%-0.19%+12.78%+51.03%+93.21%RENBLunai Bioworks0.00%0.00%-25.52%-42.93%-63.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$1.36-6.8%$1.24$0.64▼$2.92$55.38M-0.71260,508 shs45,471 shsKYTXKyverna Therapeutics$6.63-6.1%$4.49$1.78▼$7.73$305.31M3.72844,444 shs639,978 shsPBYIPuma Biotechnology$5.12-1.7%$4.79$2.32▼$6.07$262.43M1.39502,574 shs428,615 shsRENBLunai Bioworks$1.54+21.7%$2.04$1.13▼$21.00$250.24M0.543.75 million shs880,400 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics-6.85%-5.91%+23.64%+32.68%+14.29%KYTXKyverna Therapeutics-6.09%+20.11%+64.93%+64.52%+47.01%PBYIPuma Biotechnology-1.73%-0.19%+12.78%+51.03%+93.21%RENBLunai Bioworks0.00%0.00%-25.52%-42.93%-63.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRNSBarinthus Biotherapeutics 2.33Hold$3.00120.59% UpsideKYTXKyverna Therapeutics 2.60Moderate Buy$19.00186.58% UpsidePBYIPuma Biotechnology 3.00Buy$7.0036.72% UpsideRENBLunai Bioworks 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BRNS, KYTX, PBYI, and RENB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025KYTXKyverna TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$24.00 ➝ $27.0010/8/2025PBYIPuma BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)9/27/2025BRNSBarinthus BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KYTXKyverna TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PBYIPuma BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025RENBLunai BioworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/29/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $10.008/20/2025KYTXKyverna TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRNSBarinthus Biotherapeutics$14.97M3.70N/AN/A$3.23 per share0.42KYTXKyverna Therapeutics$7.03M40.79N/AN/A$6.17 per share1.07PBYIPuma Biotechnology$230.50M1.12$0.84 per share6.11$1.88 per share2.72RENBLunai BioworksN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)KYTXKyverna Therapeutics-$127.48M-$3.68N/AN/AN/AN/A-64.98%-56.17%11/12/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.985.2213.47N/A20.38%53.15%23.51%11/6/2025 (Estimated)RENBLunai Bioworks-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%N/ALatest BRNS, KYTX, PBYI, and RENB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025PBYIPuma Biotechnology$0.09N/AN/AN/AN/AN/A11/5/2025Q3 2025BRNSBarinthus Biotherapeutics-$0.45N/AN/AN/AN/AN/A8/12/2025Q2 2025KYTXKyverna Therapeutics-$1.00-$0.97+$0.03-$0.97N/AN/A8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ARENBLunai BioworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRNSBarinthus BiotherapeuticsN/A7.897.89KYTXKyverna TherapeuticsN/A5.395.39PBYIPuma Biotechnology0.101.731.62RENBLunai BioworksN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRNSBarinthus Biotherapeutics25.20%KYTXKyverna Therapeutics18.08%PBYIPuma Biotechnology61.29%RENBLunai Bioworks71.41%Insider OwnershipCompanyInsider OwnershipBRNSBarinthus Biotherapeutics10.70%KYTXKyverna Therapeutics22.00%PBYIPuma Biotechnology23.30%RENBLunai Bioworks0.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRNSBarinthus Biotherapeutics10740.72 million36.36 millionN/AKYTXKyverna Therapeutics9643.25 million33.73 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionableRENBLunai Bioworks20162.39 million171.26 millionOptionableBRNS, KYTX, PBYI, and RENB HeadlinesRecent News About These CompaniesLunai Bioworks (NASDAQ:RENB) Shares Up 12.2% - What's Next?October 1, 2025 | americanbankingnews.comLunai Bioworks unveils new corporate identitySeptember 30, 2025 | msn.comLunai Bioworks advances biomarker discovery preclinical program in Parkinson’sSeptember 25, 2025 | msn.comLunai Bioworks Inc.: Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock SplitSeptember 25, 2025 | finanznachrichten.deLunai Bioworks Inc.: Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma PartnershipsSeptember 25, 2025 | finanznachrichten.deLunai Bioworks to implement 10:1 reverse stock splitSeptember 25, 2025 | msn.comRenovaro Biosciences Announces Reverse Stock SplitSeptember 25, 2025 | msn.comLunai Bioworks stock plunges after announcing 10:1 reverse splitSeptember 25, 2025 | za.investing.comLunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma PartnershipsSeptember 25, 2025 | accessnewswire.comALunai Bioworks, Inc. to Effect 10:1 Reverse Stock SplitSeptember 24, 2025 | accessnewswire.comALunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder TherapeuticsSeptember 11, 2025 | accessnewswire.comARenovaro Inc.: Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesSeptember 9, 2025 | finanznachrichten.deLunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug DiscoverySeptember 9, 2025 | accessnewswire.comALunai Bioworks Strengthens European Strategy Through RestructuringSeptember 8, 2025 | accessnewswire.comARenovaro BioSciences retains American Defense InternationalSeptember 4, 2025 | msn.comLunai Bioworks Inc. Retains American Defense InternationalSeptember 4, 2025 | accessnewswire.comARenovaro BioSciences to change corporate name to ‘Lunai Bioworks’August 28, 2025 | msn.comRenovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced DiagnosticsAugust 27, 2025 | accessnewswire.comARenovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense RisksAugust 8, 2025 | accessnewswire.comARenovaro Biosciences Granted Nasdaq Compliance ExtensionAugust 6, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRNS, KYTX, PBYI, and RENB Company DescriptionsBarinthus Biotherapeutics NASDAQ:BRNS$1.36 -0.10 (-6.85%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$1.30 -0.06 (-4.41%) As of 10/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Kyverna Therapeutics NASDAQ:KYTX$6.63 -0.43 (-6.09%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$6.32 -0.31 (-4.68%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Puma Biotechnology NASDAQ:PBYI$5.12 -0.09 (-1.73%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$5.02 -0.10 (-1.95%) As of 10/10/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Lunai Bioworks NASDAQ:RENB$1.54 +0.28 (+21.72%) Closing price 09/30/2025Extended Trading$1.54 0.00 (0.00%) As of 09/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
